The global molecular diagnostics market size was estimated at USD 12.7 billion in 2021 and is expected to hit around USD 48.9 billion by 2030 with a registered CAGR of 16.16% from 2022 to 2030.
As there is a decline in the demand for molecular COVID-19 testing the market is expected to shrink. The diagnostics industry boomed during the outbreak of COVID-19. In order to develop novel and rapid diagnostic gifts for detection of coronavirus this market had grown drastically. Companies that were operating in the infectious diseases segment saw a spike in their revenue during the pandemic. There was a 59% rise in the revenue of Thermo Fisher Scientific due to increase in the Revenue of the diagnostics division.
The increase in the geriatric population globally and an increase in the attracting numerous diseases has led to a growth in the market. Diseases like cancer, cardiovascular diseases, neurological disorders, diabetes and obesity which could be linked to the rising geriatric population is driving the growth of the market. An increase in the incidence of infectious diseases is expected to propel the market growth.
Increase in various other diseases like HIV, HPV and STI shall help in expanding the market. There is an increase in the initiatives taken by the major market players in order to improve the access to various cost-effective resources that they offer. Infections are anticipated to drive the molecular diagnostics market growth during the forecast period till the year 2030. There is an acute and effective result generation in the molecular diagnostic tests and it has indispensable application in many disease diagnostics. These molecular tests or associated with high prices.
Factors like the technological advancements, rising elderly population and the increase in demand for genetic testing is creating great opportunities for the growth of this market. Also, an increase for self-testing diagnostic and the awareness among the patient about these faster diagnostics is creating a great growth.
Report Scope of the Molecular Diagnostics Market
|Market Size in 2022||
USD 14.75 Billion
|Market Size by 2030||
USD 48.9 Billion
|Growth Rate from 2022 to 2030||CAGR of 16.16%|
|Forecast Period||2022 to 2030|
|Segments Covered||Product, Test Location, Technology, Application, End User, and Geography|
|Companies Mentioned||Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Illumina, Inc. (US), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), PerkinElmer, Inc. (US), Abbott Laboratories (US), bioMérieux SA (France), QIAGEN N.V. (Netherlands), Myriad Genetics, Inc. (US), Agilent Technologies, Inc. (US), geneOmbio Technologies Pvt. Ltd. (India)|
The reagent segment had the largest market share until real 2021. The revenue share of the reagents segment is expected to maintain its dominance in the coming years. The segment is expected to grow during the forecast period as it is widely adopted in many research and clinical settings. Standard reagents are effective in achieving efficient and extremely accurate results.
Due to the standardization of these results, improved efficiency and the cost-effective nature the segment is expected to support the growth of the market during the forecast period. In February 2022 Roche Diagnostics extended the COVID test portfolio to new cobas 5800 system in the countries that accept the CE mark approval.
On the basis of the test locations, the central laboratories had the largest market share in the recent years. In the future the central laboratory segment is expected to grow as there are high procedure volumes for COVID testing in these laboratories. An increasing number of initiatives that are taken by the government to provide different services like reimbursement for these diagnostics test is another factor that is helping in the growth of this market. There is a growing demand in the development of molecular diagnostic platforms which can also be used in POC settings. Many major market players are designing the molecular diagnostic platforms. The growing development of this platform will offer quick POC results which are expected to provide a boost to the market.
Till the year 2021, the infectious diseases segment accounted for the largest revenue share in the molecular diagnostics market. Due to the use of the tests for the diagnosis of COVID-19 the infectious diseases segment dominated the market. In the coming years the oncology segment is expected to drive the market.
The oncology segment is expected to have a high CAGR during the forecast period. About 19.3 million cancer cases were diagnosed across the globe in the year 2020 in order to provide better access and the improvement in the oncology molecular diagnostics the British in vitro diagnostics association along with NHS England developed a commissioning framework for molecular diagnostics in oncology.
Technology Used Insights
The use of PCR technology to detect various infectious diseases or the genetic diseases is expected to drive market growth. The polymerase chain reaction segment had the largest revenue till the year 2021 due to its use in the detection of COVID-19 and other infectious diseases in the recent years. DNA sequencing processes and technologies are integrally linked to novel drug development, drug discovery and personalized medicine.
Molecular Diagnostics Market Share, By Region, 2021 (%)
|Regions||Revenuie Share in 2021 (%)|
Due to rising epidemiology of infectious and chronic diseases, the European region had a larger revenue share in the year 2021. The market is expected to grow in the coming years due to the research and development activities which are boosting the market growth. Due to an awareness amongst the consumers and the high standard of living which is creating a need for early diagnosis which helps in the growth of the market in this region. A well established and technologically advanced health care system is a major driving factor for the growth of the European region.
The Asia Pacific region is also expected to have a good growth during the forecast. As there is a great demand for these tests in the Asia Pacific region. Owing to increased market penetration and constantly expanding patient pool for early prevention, diagnosis of various therapies the market in the Asia Pacific region is expected to boost during the forecast period.
Key Market Developments
Segments Covered in the Report
(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)
By Test Location
By End User
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client